These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 38580884)

  • 1. Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability.
    Lü Y; Cho T; Mukherjee S; Suarez CF; Gonzalez-Foutel NS; Malik A; Martinez S; Dervovic D; Oh RH; Langille E; Al-Zahrani KN; Hoeg L; Lin ZY; Tsai R; Mbamalu G; Rotter V; Ashton-Prolla P; Moffat J; Chemes LB; Gingras AC; Oren M; Durocher D; Schramek D
    Mol Syst Biol; 2024 Jun; 20(6):719-740. PubMed ID: 38580884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
    Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
    J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma.
    Jethwa A; Słabicki M; Hüllein J; Jentzsch M; Dalal V; Rabe S; Wagner L; Walther T; Klapper W; ; Bohnenberger H; Rettel M; Lu J; Smits AH; Stein F; Savitski MM; Huber W; Aylon Y; Oren M; Zenz T
    Blood; 2018 Jun; 131(25):2789-2802. PubMed ID: 29653964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence, causes and impact of TP53-loss phenocopying events in human tumors.
    Fito-Lopez B; Salvadores M; Alvarez MM; Supek F
    BMC Biol; 2023 Apr; 21(1):92. PubMed ID: 37095494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 53BP1 Integrates DNA Repair and p53-Dependent Cell Fate Decisions via Distinct Mechanisms.
    Cuella-Martin R; Oliveira C; Lockstone HE; Snellenberg S; Grolmusova N; Chapman JR
    Mol Cell; 2016 Oct; 64(1):51-64. PubMed ID: 27546791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parallel CRISPR-Cas9 screens clarify impacts of p53 on screen performance.
    Bowden AR; Morales-Juarez DA; Sczaniecka-Clift M; Agudo MM; Lukashchuk N; Thomas JC; Jackson SP
    Elife; 2020 May; 9():. PubMed ID: 32441252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional profiling reveals a subset of human breast tumors that retain wt TP53 but display mutant p53-associated features.
    Benor G; Fuks G; Chin SF; Rueda OM; Mukherjee S; Arandkar S; Aylon Y; Caldas C; Domany E; Oren M
    Mol Oncol; 2020 Aug; 14(8):1640-1652. PubMed ID: 32484602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.
    Berge EO; Huun J; Lillehaug JR; Lønning PE; Knappskog S
    Biochim Biophys Acta; 2013 Mar; 1830(3):2790-7. PubMed ID: 23246812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling Breast Cancer Using CRISPR-Cas9-Mediated Engineering of Human Breast Organoids.
    Dekkers JF; Whittle JR; Vaillant F; Chen HR; Dawson C; Liu K; Geurts MH; Herold MJ; Clevers H; Lindeman GJ; Visvader JE
    J Natl Cancer Inst; 2020 May; 112(5):540-544. PubMed ID: 31589320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TSPYL5 suppresses p53 levels and function by physical interaction with USP7.
    Epping MT; Meijer LA; Krijgsman O; Bos JL; Pandolfi PP; Bernards R
    Nat Cell Biol; 2011 Jan; 13(1):102-8. PubMed ID: 21170034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanical cues control mutant p53 stability through a mevalonate-RhoA axis.
    Ingallina E; Sorrentino G; Bertolio R; Lisek K; Zannini A; Azzolin L; Severino LU; Scaini D; Mano M; Mantovani F; Rosato A; Bicciato S; Piccolo S; Del Sal G
    Nat Cell Biol; 2018 Jan; 20(1):28-35. PubMed ID: 29255172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53.
    Hu C; Zhang M; Moses N; Hu CL; Polin L; Chen W; Jang H; Heyza J; Malysa A; Caruso JA; Xiang S; Patrick S; Stemmer P; Lou Z; Bai W; Wang C; Bepler G; Zhang XM
    Cell Death Dis; 2020 May; 11(5):328. PubMed ID: 32382008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential chromatin accessibility landscape of gain-of-function mutant p53 tumours.
    Dhaka B; Sabarinathan R
    BMC Cancer; 2021 Jun; 21(1):669. PubMed ID: 34090364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo.
    Alexandrova EM; Mirza SA; Xu S; Schulz-Heddergott R; Marchenko ND; Moll UM
    Cell Death Dis; 2017 Mar; 8(3):e2661. PubMed ID: 28277540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A USP28-53BP1-p53-p21 signaling axis arrests growth after centrosome loss or prolonged mitosis.
    Lambrus BG; Daggubati V; Uetake Y; Scott PM; Clutario KM; Sluder G; Holland AJ
    J Cell Biol; 2016 Jul; 214(2):143-53. PubMed ID: 27432896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
    Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
    Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer Cells Employ Nuclear Caspase-8 to Overcome the p53-Dependent G2/M Checkpoint through Cleavage of USP28.
    Müller I; Strozyk E; Schindler S; Beissert S; Oo HZ; Sauter T; Lucarelli P; Raeth S; Hausser A; Al Nakouzi N; Fazli L; Gleave ME; Liu H; Simon HU; Walczak H; Green DR; Bartek J; Daugaard M; Kulms D
    Mol Cell; 2020 Mar; 77(5):970-984.e7. PubMed ID: 31982308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P53 ICE CRIM mouse: a tool to generate mutant allelic series in somatic cells and germ lines for cancer studies.
    Fan HH; Yu IS; Lin YH; Wang SY; Liaw YH; Chen PL; Yang TL; Lin SW; Chen YT
    FASEB J; 2019 Apr; 33(4):5571-5584. PubMed ID: 30640520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ubiquitin peptidase UCHL1 induces G0/G1 cell cycle arrest and apoptosis through stabilizing p53 and is frequently silenced in breast cancer.
    Xiang T; Li L; Yin X; Yuan C; Tan C; Su X; Xiong L; Putti TC; Oberst M; Kelly K; Ren G; Tao Q
    PLoS One; 2012; 7(1):e29783. PubMed ID: 22279545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts.
    Valletta S; Dolatshad H; Bartenstein M; Yip BH; Bello E; Gordon S; Yu Y; Shaw J; Roy S; Scifo L; Schuh A; Pellagatti A; Fulga TA; Verma A; Boultwood J
    Oncotarget; 2015 Dec; 6(42):44061-71. PubMed ID: 26623729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.